Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. (ALDX) Stock News
The latest ALDX headlines and market coverage — 8 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
היום המועד האחרון לתביעה ייצוגית נגד ALDX: רוזן, חברה שפתחה בהליכים ראשונה, מעודדת משקיעים ב-Aldeyra Therapeutics, Inc עם הפסדים של יותר מ-100 אלף דולר לקבל ייעוץ משפטי לפני המועד החשוב ב-29 במאי בתביעה ייצוגית לניירות ערך שהוגשה לראשונה על ידי המשרד – ALDX
The Rosen Law Firm reminds investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) of the May 29, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made false statements regarding inconsistent clinical trial results for reproxalap and failed to disclose material information about the company's business and operations, resulting in investor losses.
- GlobeNewswire Inc.·
מועד אחרון לתביעה ייצוגית נגד ALDX: רוזן, יועץ גלובלי מוביל, מעודד משקיעים ב-Aldeyra Therapeutics, Inc עם הפסדים של יותר מ-100 אלף דולר להשיג ייעוץ משפטי לפני המועד החשוב ב-29 במאי בתביעה ייצוגית לניירות ערך שהוגשה לראשונה על ידי המשרד – ALDX
Rosen Law Firm reminds investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) who purchased securities between November 3, 2023 and March 16, 2026 of the May 29, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made false statements regarding reproxalap clinical trial results and failed to disclose inconsistencies that rendered positive findings unreliable, causing investor losses.
- GlobeNewswire Inc.·
ALDX FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm – ALDX
Rosen Law Firm reminds investors of Aldeyra Therapeutics who purchased securities between November 3, 2023 and March 16, 2026 of the May 29, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements regarding reproxalap clinical trial results, claiming the results were inconsistent and unreliable, causing investor damages.
- GlobeNewswire Inc.·
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Vital Farms, Inc. (VITL), Super Micro Computer, Inc. (SMCI), and Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against three companies: Vital Farms (VITL) for alleged false statements regarding enterprise resource planning system implementation, Super Micro Computer (SMCI) for alleged non-disclosure of export control compliance issues, and Aldeyra Therapeutics (ALDX) for alleged misstatements regarding reproxalap clinical trials. All deadlines are set for late May 2026.
- GlobeNewswire Inc.·
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Rosen Law Firm is soliciting investors who purchased securities in Aldeyra Therapeutics, Babcock & Wilcox Enterprises, and Upstart Holdings during specified periods to join securities class action lawsuits. The firm alleges that defendants made false or misleading statements regarding clinical trial results, business operations, and financial prospects. Investors have until May 29, 2026 to serve as lead plaintiffs.
- GlobeNewswire Inc.·
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Disregarded FDA Requirements: Levi & Korsinsky
Aldeyra Therapeutics faces a securities class action lawsuit after an FDA Complete Response Letter exposed alleged failures in clinical trial evidence for its lead dry eye disease drug reproxalap. ALDX shares collapsed 70.7% on March 17, 2026, closing at $1.24. Investors who purchased securities between November 3, 2023 and March 16, 2026 can apply to be lead plaintiff by May 29, 2026.
- GlobeNewswire Inc.·
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
Aldeyra Therapeutics faces a securities class action lawsuit after the FDA rejected its lead drug candidate reproxalap, citing inconsistent and unreliable clinical trial data. ALDX stock plummeted 70.7% ($2.99 per share) on March 17, 2026. Investors who purchased shares between November 3, 2023 and March 16, 2026 may be eligible to participate in the class action, with the lead plaintiff application deadline set for May 29, 2026.
- GlobeNewswire Inc.·Bearish
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Aldeyra Therapeutics, alleging the company made false and misleading statements about reproxalap clinical trial results. The lawsuit covers purchases between November 3, 2023 and March 16, 2026, with a lead plaintiff deadline of May 29, 2026.